MEDI-PHYSICS WILL MARKET SUMMA MEDICAL BLOOD CLOT IMAGING AGENT
Executive Summary
MEDI-PHYSICS WILL MARKET SUMMA MEDICAL BLOOD CLOT IMAGING AGENT under a licensing agreement announced Oct. 15. Roche's Medi-Physics subsidiary will have exclusive worldwide rights to Summa's Summa-Clot monoclonal antibody-based in vivo diagnostic and "will pay Summa an undisclosed amount of cash and a royalty on all adjusted gross sales in the United States and abroad," Summa said. Summa will conduct clinical trials of the blood clot diagnostic at the University of Oklahoma under an IND. The in vivo diagnostic agent is being investigated for use in blood clot-related disorders such as heart attacks, strokes and other forms of thrombosis and embolism. Summa said it expects Medi-Physics to conduct additional clinical trials. In a related matter, Summa announced Oct. 1 that it entered into an agreement with Medi-Physics, giving the Hoffmann-LaRoche division an option to purchase the assets of Summa's radiopharmacy business for approximately $7 mil. The transaction covers 10 Summa-owned pharmacies in Chicato, New Orleans, Seattle, and Washington, D.C., with the remainder in California. The option term expires on Nov. 15
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth